Kingstone Capital Partners Texas, LLC Pyxis Oncology, Inc. Transaction History
Kingstone Capital Partners Texas, LLC
- $624 Billion
- Q2 2025
A detailed history of Kingstone Capital Partners Texas, LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Kingstone Capital Partners Texas, LLC holds 33,600 shares of PYXS stock, worth $34,944. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,600Holding current value
$34,944% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PYXS
# of Institutions
80Shares Held
22.1MCall Options Held
138KPut Options Held
30.9K-
Laurion Capital Management LP New York, NY3.63MShares$3.77 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$2.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.49MShares$2.58 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$2.24 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.1MShares$1.14 Million0.07% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $36.5M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...